Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

DALLAS, Texas (July 14, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the Company was chosen for Breakthrough Technologies Award at OIS Retina Innovation Summit in New York. The award is granted to a single company that demonstrates groundbreaking technological innovation, selected by Medical and Industry Peers.

At the OIS Retina Innovation Summit’s Spotlight on Breakthrough Technologies session, Samarendra Mohanty, Ph.D., Co-Founder, President and Chief Scientific Officer of Nanoscope, gave a presentation on the Company’s Platform technologies on Multi-Characteristic Opsin (MCO) and non-viral laser gene delivery. He also shared progress on U.S. clinical trials of MCO-010 for retinitis pigmentosa and Stargardt disease.

“Amongst the many dedicated industry leaders in the retina space who attended the OIS Retina Innovation Summit, it is an honor for us to be recognized by OIS,” said Nanoscope’s Co-Founder and CEO, Sulagna Bhattacharya. “We are not only encouraged by the progress we are making in advancing our MCO gene therapy platform, but also by the recognition from our industry of our efforts to improve the standard of care for patients suffering from retinal degenerative diseases.”

Results from Nanoscope’s Phase 2b RESTORE trial for retinitis pigmentosa, its most advanced clinical program, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in Q1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:

Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

On July 14, 2022   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.